T cell activation + checkpoint inhibition: the 6-month survival rate of triple immunotherapy for glioblastoma multiforme (GBM) is 80%!

November 7, 2019 / Biovalley BIOON / -- new diagnosis of evaluation of triple immunotherapy (ino-5401, ion-9012, libtayo) was announced at the 2019 annual meeting of cancer immunotherapy Society (SITC) held in Maryland recently by inovio Pharma, an American vaccine cancer immunotherapy company The results of phase II clinical study (nct03491683) of glioblastoma multiforme (GBM) were positive Ino-5401 is a T cell activated immunotherapy that encodes three tumor associated antigens (hTERT, WT1, PSMA) It has the potential to form a powerful cancer immunotherapy program with immunocheckpoint inhibitors The National Cancer Institute (NCI) has listed these three antigens as important cancer antigens before, and listed them as a high priority project in the development of cancer immunotherapy; these three antigens are overexpressed in a variety of human cancers, and often mutated, which may target these antigens to effectively treat cancer patients Ino-9012 encodes interleukin-12 (IL-12), which is a T cell immunoactivator Previously published non-human primate test data showed that the combination of ino-5401 and ino-9012 could generate a strong T cell immune response against hTERT, WT1 and PSMA Libtayo (cemiplimab) is a tumor immunotherapy developed by Sanofi and regenerator It is an all human monoclonal antibody against the receptor PD-1 (programmed cell death protein-1) of immune checkpoint Libtayo belongs to PD - (L) 1 tumor immunotherapy, which is a kind of tumor immunotherapy with great attention at present It aims to use the immune system of human body to resist cancer, and block the PD-1 / PD-L1 signal pathway to make cancer cells die It has the potential to treat various types of tumor The data from the 52 patients in the critical period of the clinical trial showed that 80% (16 / 20) of the MGMT gene promoter methylation patients and 75% (24 / 32) of the unmethylated patients had no progress within 6 months of treatment (pfs6), which greatly exceeded the historical standard nursing data In addition, this immunotherapy combination with PD-1 checkpoint inhibitor also shows supportive safety, tolerance and immunogenicity data, and has acceptable safety consistent with libtayo and inovio platform technologies Most of the subjects showed T cell immune response to one or more tumor associated antigens encoded by ino-5401 In the study, immune responses to all three tumor associated antigens were confirmed Inovio plans to release 12-month and 18 month overall survival data in 2019 David, CO lead investigator of the study and clinical director of neurooncology, Dana Farber Cancer Institute "This innovative trial provides promising information that the combination of T-cell facilitation therapies ino-5401 and ino-9012 with an immunocheckpoint inhibitor libtayo may provide clinically significant benefits in this difficult to treat disease," Dr Reardon said Dr J Joseph Kim, President and CEO of inovio, said: "our latest data shows the potential of immunotherapy with tumor associated antigens in cancer treatment Our goal in this GBM trial is to improve patients' progression free survival and overall survival rate The treatment standard and clinical results of this disease have not been significantly improved in decades Previously, the use of other checkpoint inhibitors alone in GBM trials did not show any significant clinical benefits However, the addition of ino-5401 and its ability to produce antigen-specific T cells showed early effective signals in progression free survival We look forward to reporting more data, including next year's total survival of 12 and 18 months of the trial " Source of original text: 80% 6-month progress free survival in phase 2 glioblastoma multiform (GBM) study with ino-5401 in combination with PD-1 inhibitor libtayo ® (cemiplimab)